1921
Volume 73, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Therapeutic failure in the treatment of cutaneous leishmaniasis (CL) occurs in 5% of patients infected by . This study evaluates the use of topically applied granulocyte macrophage colony-stimulating factor (GM-CSF) combined with the standard dose of antimony to treat refractory cases of CL. Five patients who had received three courses or more of antimony were enrolled in an open-label clinical trial. One to 2 mL of the GM-CSF solution (10 μg/mL in 0.9% saline) was reapplied topically, and dressings were changed three times per week for 3 weeks, associated with standard parenteral antimony (20 mg kg day for 20 days). All the patients healed their CL ulcers; 3 healed within 50 days (21, 27, and 44 days) and 2 in 118 and 120 days after beginning therapy. There were no side effects. This study shows that combined topically applied GM-CSF and antimony can be effective and well tolerated in the treatment of relapsed CL.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2005.73.79
2005-07-01
2017-07-28
Loading full text...

Full text loading...

/deliver/fulltext/14761645/73/1/0730079.html?itemId=/content/journals/10.4269/ajtmh.2005.73.79&mimeType=html&fmt=ahah

References

  1. Modabber F, 1987. The Leishmaniases. Maurice J, Pearce AM, eds. Tropical Diseases Research: A Global Partnership. Eight Programme Report. Geneva: World Health Organization, 99–112.
  2. Bittencourt AL, Barral-Netto M, 1995. Leishmaniasis. Doerr W, Seifert G, eds. Tropical Pathology. Heidelberg: Springer, 597–651.
  3. Berman JD, 1997. Human leishmaniasis: clinical, diagnostic and chemotherapeutic development in the last 10 years. Clin Infect Dis Apr 24 : 684–703.
  4. Barral-Netto M, Machado P, Bittencourt AL, Barral A, 1997. Recent advances in the pathophisiology and treatment of human cutaneous leishmaniasis. Curr Opin Dermatol 4 : 51–58.
  5. Sampaio SA, Castro RM, Dilon NL, Martins JE, 1971. Treatment of mucocutaneous (American) leishmaniasis with amphetericin B: report of 70 cases. Int J Dermatol 10 : 179–181.
  6. Soto-Mancipe J, Grogl M, Berman JD, 1993. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 16 : 417–425.
  7. Koff AB, Rosen T, 1994. Treatment of cutaneous leishmaniasis. J Am Acad Dermatol 31 : 693–708.
  8. Lieschke GL, Burgess AW, 1992. Granulocyte colony-stimulating factor and granulocyte-macrophage-colony stimulating factor. N Engl J Med 327 : 99–106.
  9. Jones TC, 1996. The effect of granulocyte-macrophage colony-stimulating factor (rhGM-CSF) on macrophage function in microbial disease. Med Oncol 13 : 141–147.
  10. Ho JL, Reed SG, Wick EA, Giordano M, 1990. Granulocyte-macrophage and macrophage colony stimulating factors activate intramacrophage killing of Leishmania mexicana amazonensis. J Infect Dis 162 : 224–230.
  11. Al-Zamel F, Al-Shammary FJ, El-Shewemi S, 1996. Enhancement of leishmanicidal activity of human macrophages against Leishmania major and Leishmania donovani infection using recombinant human granulocyte-macrophage colony-stimulating factor. Zentralbl Bakteriol. 285 : 92–105.
  12. Jones TC, 1993. The effects of rhGM-CSF on macrophage function. Eur J Cancer 29 (Suppl 3): 10–13.
  13. Marques da Costa R, Aniceto C, Jesus FM, Mendes M, 1994. Quick healing of leg ulcers after molgramostim. Lancet 344 : 481–482.
  14. Kurzrock R, Talpaz M, Gutterman JU, 1992. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia. Am J Med 93 : 41–48.
  15. Jaschke E, Zabernigg A, Gattinger C, 1999. Recombinant human granulocyte-macrophage colony-stimulating factor applied locally in low doses enhances healing and prevents recurrence of chronic venous ulcers. Int J Dermatol 38 : 380–386.
  16. Robson MC, Phillips TJ, Falanga V, Odenheimer DJ, Parish LC, Jensen JL, Steed DL, 2001. Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Repair Regen 9 : 347–352.
  17. Almeida RP, D’Oliveira A Jr, Machado P, Bacellar O, Ko AI, Ribeiro de Jesus A, Mobashery N, Santos JB, Carvalho EM, 1999. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous leishmaniasis. J Infect Dis 180 : 1735–1737.
  18. Santos JB, de Jesus AR, Machado PR, Magalhães A, Salgado S, Carvalho EM, Almeida RP, 2004. Recombinant human GM-CSF applied topically in low doses plus antimony enhances healing of cutaneous leishmaniasis ulcers: a randomized, double-blind study. J Infect Dis 190 : 1793–1796.
  19. Robson M, Kucukcelebi A, Carp SS, 1994. Effects of granulocyte-macrophage colony-stimulating factor on wound contraction. Eur J Clin Microbiol Infect Dis 13 : 41–46.
  20. Kaplan G, Walsch G, Guido LS, Meyn P, Burkhardt RA, Abalos RM, Barker J, Frindt PA, Fajardo TT, Celona R, 1992. Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony–stimulating factor. Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med 175 : 1717–1728.
  21. Kucukcelebi A, Carp SS, Haward PG, 1992. Granulocyte-macrophage colony-stimulating factor reverses the inhibition of wound contraction caused by bacterial contamination. Wounds 4 : 241–247.
  22. Doherty TM, Coffman RL, 1993. Leishmania antigens presented by GM-CSF-derived macrophages protect susceptible mice against challenge with Leishmania major. J Immunol 150 : 5476–5483.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2005.73.79
Loading
/content/journals/10.4269/ajtmh.2005.73.79
Loading

Data & Media loading...

  • Received : 02 Sep 2004
  • Accepted : 26 Feb 2005

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error